within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EA03_Nilotinib;
model Nilotinib 
   extends Pharmacolibrary.Drugs.ATC.L.L01EA03;

  annotation(Documentation(
    info ="<html><body><p>Nilotinib is a second-generation oral tyrosine kinase inhibitor targeting BCR-ABL and is used primarily in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (CML). It is currently approved and widely used in clinical practice for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult patients with chronic myeloid leukemia following oral administration under fasting conditions.</p><h4>References</h4><ol><li><p>Trent, J, &amp; Molimard, M (2011). Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors. <i>Seminars in oncology</i> 38 Suppl 1 S28–S33. DOI:<a href=&quot;https://doi.org/10.1053/j.seminoncol.2011.01.014&quot;>10.1053/j.seminoncol.2011.01.014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21419933/&quot;>https://pubmed.ncbi.nlm.nih.gov/21419933</a></p></li><li><p>Xia, B, et al., &amp; Lin, TH (2012). Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. <i>Biopharmaceutics &amp; drug disposition</i> 33(9) 536–549. DOI:<a href=&quot;https://doi.org/10.1002/bdd.1821&quot;>10.1002/bdd.1821</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23097199/&quot;>https://pubmed.ncbi.nlm.nih.gov/23097199</a></p></li><li><p>Yin, OQ, et al., &amp; Schran, H (2010). Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. <i>Journal of clinical pharmacology</i> 50(8) 960–967. DOI:<a href=&quot;https://doi.org/10.1177/0091270009346061&quot;>10.1177/0091270009346061</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20498287/&quot;>https://pubmed.ncbi.nlm.nih.gov/20498287</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Nilotinib;
